Author:
Collins R,Trowman R,Norman G,Light K,Birtle A,Fenwick E,Palmer S,Riemsma R
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443
2. Cabrespine A, Guy L, Chollet P, Fleury J, Gachon F, Curé H, Mouret-Reynier M, Van Praagh I, Penault-Llorca F, Bay J . Phase II study of paclitaxel carboplatin combination versus mitoxantrone in patients with hormone-refractory prostate cancer [conference abstract: no. 301]. In: 2005 Prostate Cancer Symposium. Alexandria, VA: American Society of Clinical Oncology
3. Cancer Research UK (2004) CancerStats incidence – UK [web page on the Internet] London: Cancer Research UK
4. Cell Genesys. GVAX® Prostate Cancer Vaccine vs Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer [web page on the Internet] Bethesda, MD: National Institutes of Health
5. Centre for Reviews and Dissemination (2001) Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for those Carrying out or Commissioning reviews [CRD report 4] CRD Reports. York: Centre for Reviews and Dissemination
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献